newsfilter
← Latest News
GlobeNewswire·

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company

Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s...